Patients with hematologic malignancies frequently present with anemia and are likely to face worsening of this condition while undergoing induction therapy, as well as repetitive consolidation, or maintenance therapy. While acute reversal of anemias still requires blood transfusions, epoetin alpha and beta are now available to treat both disease and treatment-related anemias. Current guidelines developed by ASCO recommend use of erythropoietin for patients with a hemoglobin of less than 10 g/dL in the setting of treated or untreated myelodysplasia. Either treatment-related or disease-associated anemia can also be alleviated by the judicious use of erythropoietin.4

0 0

Post a comment